Literature DB >> 11819390

Current medical therapy for ulcerative colitis.

Chang-Tai Xu, Bo-Rong Pan.   

Abstract

Entities:  

Year:  1999        PMID： 11819390      PMCID： PMC4688505          DOI： 10.3748/wjg.v5.i1.64

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


× No keyword cloud information.
  30 in total

Review 1.  Genetics of inflammatory bowel disease: implications for the future.

Authors:  A S Peña; J B Crusius
Journal:  World J Surg       Date:  1998-04       Impact factor: 3.352

Review 2.  Optimizing therapy for inflammatory bowel disease.

Authors:  M Robinson
Journal:  Am J Gastroenterol       Date:  1997-12       Impact factor: 10.864

Review 3.  Immunosuppressive treatment for refractory ulcerative colitis--where do we stand and where are we going?

Authors:  J Schölmerich
Journal:  Eur J Gastroenterol Hepatol       Date:  1997-09       Impact factor: 2.566

Review 4.  From basic science to future medical options for treatment of ulcerative colitis.

Authors:  J Rask-Madsen
Journal:  Eur J Gastroenterol Hepatol       Date:  1997-09       Impact factor: 2.566

Review 5.  Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease.

Authors:  A N Wadworth; A Fitton
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

6.  A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.

Authors:  L Kam; H Cohen; C Dooley; P Rubin; J Orchard
Journal:  Am J Gastroenterol       Date:  1996-07       Impact factor: 10.864

Review 7.  The modern medical management of acute, severe ulcerative colitis.

Authors:  J F Marion; D H Present
Journal:  Eur J Gastroenterol Hepatol       Date:  1997-09       Impact factor: 2.566

8.  Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.

Authors:  W Kruis; E Schütz; P Fric; B Fixa; G Judmaier; M Stolte
Journal:  Aliment Pharmacol Ther       Date:  1997-10       Impact factor: 8.171

9.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors:  D Rachmilewitz
Journal:  BMJ       Date:  1989-01-14

10.  Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis.

Authors:  L R Sutherland; G R May; E A Shaffer
Journal:  Ann Intern Med       Date:  1993-04-01       Impact factor: 25.391
View more
  6 in total

Review 1.  An analysis of 10218 ulcerative colitis cases in China.

Authors:  Xue-Liang Jiang; Hui-Fei Cui
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

2.  Morphological study on colonic pathology in ulcerative colitis treated by moxibustion.

Authors:  Huan-Gan Wu; Li-Bin Zhou; Da-Ren Shi; Shi-Min Liu; Hui-Rong Liu; Bi-Meng Zhang; Han-Ping Chen; Lin-Shan Zhang
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

3.  Effects of Rheum tanguticum polysaccharide on TNBS -induced colitis and CD4+T cells in rats.

Authors:  Li Liu; Zhi-Peng Wang; Chang-Tai Xu; Bo-Rong Pan; Qi-Bing Mei; Yin Long; Jia-Yun Liu; Si-Yuan Zhou
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

4.  Significance of changes of gastrointestinal peptides in blood and ileum of experimental spleen deficiency rats.

Authors:  Li-Sheng Li; Rui-Yao Qu; Wei Wang; Hua Guo
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

5.  Role of Rheum Polysaccharide in the cytokines produced by peripheral blood monocytes in TLR4 mediated HLA-B27 associated AAU.

Authors:  Xuhui Liu; Xiaofeng Hu; Xiaosheng Zhang; Zhongqiu Li; Hong Lu
Journal:  Biomed Res Int       Date:  2013-09-16       Impact factor: 3.411

6.  Pectin Film Coated Pellets for Colon-targeted Delivery of Budesonide: In-vitro/In-vivo Evaluation in Induced Ulcerative Colitis in Rat.

Authors:  Jaleh Varshosaz; Jaber Emami; Naser Tavakoli; Mohsen Minaiyan; Nakisa Rahmani; Farid Dorkoosh; Parvin Mahzouni
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.